Skip to main content
. Author manuscript; available in PMC: 2022 Feb 12.
Published in final edited form as: J Med Chem. 2021 Jul 16;64(15):11045–11062. doi: 10.1021/acs.jmedchem.1c00439

Figure 5.

Figure 5.

26f degrades enzalutamide (5) resistance-conferring escape mutant AR. EnzR LNCaP cells (MR49F cells) (top panel) or 22RV1 cells (bottom panel) were maintained in a charcoal-stripped serum-containing medium for 2 d and treated with 0.1 nM R1881 (agonist) and a titration of the 26f or 5, as indicated in the figure. Twenty-four hours after treatment, cells were harvested and the protein was extracted and blotted with an AR-N20 antibody. Blots were stripped and reprobed with a GAPDH antibody.